Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neurocrine Biosciences (NBIX) Inventory (2017 - 2025)

Neurocrine Biosciences (NBIX) has disclosed Inventory for 8 consecutive years, with $69.0 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Inventory rose 20.21% year-over-year to $69.0 million, compared with a TTM value of $69.0 million through Dec 2025, up 20.21%, and an annual FY2025 reading of $69.0 million, up 20.21% over the prior year.
  • Inventory was $69.0 million for Q4 2025 at Neurocrine Biosciences, roughly flat from $69.3 million in the prior quarter.
  • Across five years, Inventory topped out at $69.3 million in Q3 2025 and bottomed at $25.5 million in Q3 2021.
  • Average Inventory over 4 years is $42.4 million, with a median of $37.2 million recorded in 2024.
  • Peak annual rise in Inventory hit 59.03% in 2024, while the deepest fall reached 11.38% in 2024.
  • Year by year, Inventory stood at $25.5 million in 2021, then skyrocketed by 50.2% to $38.3 million in 2023, then soared by 49.87% to $57.4 million in 2024, then grew by 20.21% to $69.0 million in 2025.
  • Business Quant data shows Inventory for NBIX at $69.0 million in Q4 2025, $69.3 million in Q3 2025, and $56.9 million in Q2 2025.